Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD and Schering Plough product reduces LDL and CRP

MSD and Schering Plough product reduces LDL and CRP

14th March 2006

Vytoril, the drug of MSD and Schering-Plough, has emerged from its latest clinical trial in a positive light.

The most recent tests carried out involving the cholesterol-reducing pharmaceutical product found that it significantly reduced the levels of LDL cholesterol and C-reactive protein (CRP) in patients with high cholesterol.

Results showed that the drug was far more effective than another MSD drug, Zocor. Vytoril reduced LDL by an average 52.5 per cent and CRP by an average of 31 per cent compared to Zocor’s 38 per cent reduction in LDL and 14.3 per cent for CRP.

“In this analysis, while both treatments yielded LDL cholesterol and CRP reductions, we saw that Vytorin lowered LDL cholesterol and CRP by a significantly greater amount in more patients than Zocor,” said Christie M Ballantyne, director of the Centre for Cardiovascular Disease Prevention, Methodist DeBakey Heart Centre, Houston, Texas.

While no specific relationship between CRP and cardiovascular disease (CVD) has yet been established, it is believed by the American Heart Foundation that CRP is an emerging risk factor for CVD, according to MSD.

track© Adfero Ltd

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.